Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ashley M Holder"'
Autor:
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0151121 (2016)
Externí odkaz:
https://doaj.org/article/3f58caf117d4453f9c614ffcebd247ec
Autor:
Priscilla F McAuliffe, Kurt W Evans, Argun Akcakanat, Ken Chen, Xiaofeng Zheng, Hao Zhao, Agda Karina Eterovic, Takafumi Sangai, Ashley M Holder, Chandeshwar Sharma, Huiqin Chen, Kim-Anh Do, Emily Tarco, Mihai Gagea, Katherine A Naff, Aysegul Sahin, Asha S Multani, Dalliah M Black, Elizabeth A Mittendorf, Isabelle Bedrosian, Gordon B Mills, Ana Maria Gonzalez-Angulo, Funda Meric-Bernstam
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0136851 (2015)
Breast cancer patients who are resistant to neoadjuvant chemotherapy (NeoCT) have a poor prognosis. There is a pressing need to develop in vivo models of chemo resistant tumors to test novel therapeutics. We hypothesized that patient-derived breast c
Externí odkaz:
https://doaj.org/article/7b19cd5ca69e48e9bcf7d70a6c6b420b
Autor:
Haifa Shen, Xuewu Liu, Mauro Ferrari, Ashley M. Holder, Xiaojun Xia, Junhua Mai, Dechen Zhang, Jianliang Shen, Joy Wolfram, Xinyu Zhou, Xiaoyan Wu, Chaofeng Mu
Purpose: Triple-negative breast cancer (TNBC) is a clinically aggressive disease with poor prognosis. Conventional chemotherapeutics are generally able to shrink the tumor mass, but often fail to completely eradicate cancer stem–like cells (CSCs) t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d10d491dc01ef092985ef778c1c915e2
https://doi.org/10.1158/1078-0432.c.6527535
https://doi.org/10.1158/1078-0432.c.6527535
Autor:
Haifa Shen, Xuewu Liu, Mauro Ferrari, Ashley M. Holder, Xiaojun Xia, Junhua Mai, Dechen Zhang, Jianliang Shen, Joy Wolfram, Xinyu Zhou, Xiaoyan Wu, Chaofeng Mu
Supplementary Data Supplementary Methods Fig. S1. Increased CD44+CD24-ESA+ cell subpopulation in (A) SUM159 and (B) MDA-MB-231 cells after docetaxel treatment. *, p< 0.05; **, p< 0.01 (compared to untreatment controls). Analysis of apoptotic (C) SUM1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c65118ab9645adc7cf82b77efc3d025
https://doi.org/10.1158/1078-0432.22470363.v1
https://doi.org/10.1158/1078-0432.22470363.v1
Publikováno v:
Journal of Surgical Research. 270:335-340
Background The Blue Ridge Institute for Medical Research (BRIMR) reports a ranking of surgical department NIH funding each fiscal year based on more than 41,000 individual investigators. This report is used to measure the research productivity of the
Autor:
Brian R. Gastman, Martin D. Fleming, Anthony J. Olszanski, Jeffrey A. Sosman, Samantha Guild, April K.S. Salama, Susan M. Swetter, Dominick J. DiMaio, Douglas B. Johnson, Richard W. Joseph, Ryan M. Lanning, Rohit Sharma, Joseph J. Skitzki, Anjela Galan, Alison B. Durham, Anita M. Engh, Joel M. Baumgartner, Kenneth F. Grossmann, Genevieve M. Boland, Kari Kendra, Bartosz Chmielowski, Patrick A. Ott, Mark R. Albertini, Giorgos C. Karakousis, Kim Margolin, Nicole R. McMillian, Julie R. Lange, Merrick I. Ross, Christopher A. Barker, Evan Wuthrick, John A. Thompson, Ryan C. Fields, Ashley M. Holder
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:364-376
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded to include pathways for treatment of microscopic satellitosis (added in v2.2020), and the following Principles sections: Molecular Testing (added in v2.2019), Sys
Autor:
Bogdan Milicevic, Jessica Domitrovic, Ashley M. Holder, Milos Kojic, Miljan Milosevic, Vladimir Simic
Publikováno v:
Book of Proceedings: 1st International Conference on Chemo and BioInformatics.
Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has become an essential part of the management of peritoneal carcinomatosis [1,2]. HIPEC is a cancer treatment procedure that involves filling the abdominal c
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Melanoma is the most lethal form of skin cancer in the United States. Current American Joint Committee on Cancer (AJCC) staging uses Breslow depth and ulceration as the two primary tumor factors that predict metastatic risk in cutaneous melanoma. Ear
Autor:
Ashley M. Holder, Arturas Ziemys
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Background In staging patients with clinical stage I-II melanoma, the sentinel lymph node (SLN) is the most important prognostic indicator; however, the false negative rate of SLN biopsy (SLNB) is 15%. Methods Nine patients with clinical Stage I-II m
Publikováno v:
Advanced NanoBiomed Research, Vol 1, Iss 10, Pp n/a-n/a (2021)
Treatment of peritoneal surface malignancies with cytoreductive surgery and HIPEC (CRS/HIPEC) has a substantial risk of local recurrence and causes off‐target toxicity. HIPEC is reinvented utilizing a gold nanorod (GNR) platform to provide surgical